RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 - KXXV-TV News Channel 25 - Central Texas News and Weather for Waco, Temple, Killeen |

RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ResMed Inc.

Fourth quarter revenue of $415 million

Fourth quarter GAAP earnings per share of $0.61 and non-GAAP earnings per share of $0.64

Operating cash flow of $115.6 million in the fourth quarter

Quarterly dividend increased by 12% to $0.28 per share

SAN DIEGO, July 31, 2014 /PRNewswire/ -- ResMed Inc. (NYSE: RMD) today announced results for its fourth quarter and for the fiscal year ended June 30, 2014.  Revenue for the quarter was $415.2 million, flat compared to the quarter ended June 30, 2013 (a 1 percent decrease on a constant currency basis). Net income was $87.7 million, an increase of 20 percent compared to the quarter ended June 30, 2013. Diluted earnings per share for the quarter were $0.61, an increase of 22 percent compared to the quarter ended June 30, 2013. 

The results for the quarter ended June 30, 2014 were impacted by a $6.3 million ($4.2 million, net of tax) expense for restructuring charges relating to employee termination benefits associated with our reorganization of our commercial and research and development teams.  Non-GAAP net income for the quarter ended June 30, 2014 was $92.0 million, a 1 percent  increase compared to the quarter ended June 30, 2013 (non-GAAP measures exclude the impact of the restructuring expenses in the current quarter and the charge for Sydney University education, research and settlement expenses in the prior year quarter).  Non-GAAP diluted earnings per share for the quarter were $0.64, a 3 percent increase compared to the quarter ended June 30, 2013.  

"Our fourth quarter results were lower than anticipated, the result of softer sales in the Americas, partially offset by good growth in our international markets," said ResMed Chief Executive Officer Mick Farrell.  "We continue to benefit from our globally diversified business, with constant currency revenue growth of 5 percent in our combined Europe and Asia-Pacific businesses."

Highlighting ResMed's new products, Farrell continued, "We see good adoption of our AirFitP10 nasal pillows system which is currently the market leader among new patients, and although it is early, we are seeing encouraging traction for our AirFitN10 nasal mask and AirFitF10 full-face mask which were launched in the fourth quarter around the world. On the flow generator side in the fourth quarter, we launched the Astral™ platform, our new generation of life support ventilators, and are seeing strong uptake in Europe and Asia as sales begin to ramp. During the fourth quarter, we received FDA clearance for the Astral platform in the U.S. and anticipate a U.S. launch by the end of the calendar year." 

Farrell concluded, "We remain focused on capital management, as we continued to repurchase our shares during the quarter.  And today, we announced an increase in our quarterly dividend – the second increase since we began paying a dividend in September 2012.  We are executing against our Three Horizons strategy and expect to return to constant currency top-line growth as we ramp up our new product offerings over fiscal year 2015.  These ResMed solutions are emblematic of our goal to improve patient outcomes and quality of life, while reducing costs for global healthcare systems. In tougher times, we remain committed to disciplined management of our expenses while appropriately funding our long-term opportunities.  We remain excited about the long-term prospects of our business, with ongoing growth opportunities in treating sleep-disordered breathing, chronic obstructive pulmonary disease, and cardiorespiratory diseases."

Analysis of fourth quarter and fiscal year 2014 results
In the fourth quarter of fiscal year 2014, revenue outside the Americas was $200.3 million, a 9 percent increase over the prior year's quarter (5 percent on a constant currency basis). Revenue in the Americas was $214.9 million, a 7 percent decrease compared to $230.3 million in the prior year's quarter.

Gross margin in the fourth quarter was 62.9 percent, 20 basis points higher than the same period in the prior year, due to favorable foreign currency movements, manufacturing improvements, and favorable geographic mix, which were partially offset by declines in average selling prices.

Selling, general and administrative expenses were $122.2 million for the quarter, a 6 percent increase (also a 6 percent increase on a constant currency basis) over the quarter ended June 30, 2013.  SG&A costs were 29.4 percent of revenue in the quarter, compared to 27.8 percent in the quarter ended June 30, 2013, primarily due to higher legal expenses associated with patent litigation.   

Research and development expenses were $31.8 million for the quarter, or 7.7 percent of revenue.  R&D expenses increased by 1 percent (a 3 percent increase on a constant currency basis) compared to the quarter ended June 30, 2013. 

Operating profit for the fourth quarter was $98.5 million and cash flow from operations was $115.6 million.

ResMed amortized acquired intangibles of $2.4 million ($1.8 million, net of tax) during the quarter.  Stock-based compensation costs incurred during the quarter of $10.8 million ($7.6 million, net of tax) consisted of expenses associated with stock options, restricted stock units, and the company's employee stock purchase plan.  

For the 12 months ended June 30, 2014, revenue was $1,555.0 million, a 3 percent increase over the 12 months ended June 30, 2013 (a 2 percent increase on a constant currency basis).  For the 12 months, net income was $345.3 million, a 12 percent increase compared to the 12 months ended June 30, 2013.  Diluted earnings per share for the 12 months were $2.39 per diluted share, a 14 percent increase compared to the 12 months ended June 30, 2013.

Share repurchase program
During the quarter, the company also repurchased 0.8 million shares at a cost of $40.4 million, as part of its ongoing capital management program.  For the 12 months ended June 30, 2014 the company repurchased 4.4 million shares at a cost of $208.1 million.

Dividend program
The ResMed board of directors has today declared a quarterly dividend of $0.28 per share, which represents a 12 percent increase from the previous quarterly dividend of $0.25.  The dividend will have a record date of Aug. 21, 2014, and be payable on Sept. 18, 2014. The dividend will be paid in U.S. currency to holders of ResMed's common stock trading on the New York Stock Exchange. Holders of Chess Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares.  The ex-dividend date will be Aug. 19, 2014 for common stock holders and for CDI holders.  ResMed has received a waiver from the ASX's settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from Aug. 19, 2014 through Aug. 21, 2014, inclusive.

Webcast details
ResMed will discuss its financial and business results as well as its business outlook on its webcast at 1:30 p.m. U.S. Pacific Daylight Time today. The live webcast of the call can be accessed on ResMed's website at www.resmed.com. Please note that the format of the call has not changed. Please allow extra time prior to the call to visit the website and download the streaming media player (Windows Media Player), required to listen to the internet broadcast. The online archive of the broadcast will be available after the live call on ResMed's website. In addition, a telephone replay of the conference call will be available approximately 90 minutes after the call by dialing 630-652-3042 (domestic) and +1 630-652-3042 (international) and entering a passcode of 37658760.  The telephone replay will be available from July 31, 2014 until Aug. 14, 2014.

About ResMed
ResMed changes lives by developing, manufacturing and distributing medical equipment for treating, diagnosing, and managing sleep-disordered breathing, COPD, and other chronic diseases. We develop innovative products and solutions to improve the health and quality of life of those who suffer from these conditions, and we work to raise awareness of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

Safe harbor statement
Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements -- including statements regarding ResMed's projections of future revenue or earnings,  expenses, new product development, new product launches and new markets for its products --  are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed's periodic reports on file with the U.S. Securities & Exchange Commission.  ResMed does not undertake to update its forward-looking statements.

Investors:
Agnes Lee
Senior Director, Investor Relations
(858) 836-5971
investorrelations@resmed.com

News Media:
Gretchen Griswold
Director, Global Corporate Communications
(858) 836-6789
news@resmed.com

 

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Income (Unaudited)

(In thousands, except per share data)



Three Months Ended

June 30,

Twelve Months Ended

June 30,


2014

2013

2014

2013






Net revenue

$415,211

$414,607

$1,554,973

$1,514,457

Cost of sales

153,953

154,759

565,187

573,800

Gross profit

261,258

259,848

989,786

940,657






Operating expenses:





Selling, general and administrative

122,242

115,057

450,414

430,802

Research and development

31,796

31,390

118,226

120,124

Restructuring expenses(1)

6,326

-

6,326

-

Education, research and settlement charge (1)

-

24,765

-

24,765

Amortization of acquired intangible assets

2,408

2,471

9,733

10,142

Total operating expenses

162,772

173,683

584,699

585,833

Income from operations (1)

98,486

86,165

405,087

354,824

Other income (expenses), net:





Interest income (expense), net

5,925

7,439

25,107

32,486

Other, net

2,224

(5,777)

884

(2,191)

Total other income (expenses), net

8,149

1,662

25,991

30,295

Income before income taxes

106,635

87,827

431,078

385,119

Income taxes

18,897

14,814

85,805

77,986

Net income (1)

$87,738

$73,013

$345,273

$307,133

Basic earnings per share

$0.62

$0.51

$2.44

$2.15

Diluted earnings per share (1)

$0.61

$0.50

$2.39

$2.10

Non-GAAP diluted earnings per share, excluding the impact of restructuring expenses and the education, research and settlement charge (1)

$0.64

$0.62

$2.42

$2.22






Basic shares outstanding

140,537

142,669

141,474

142,954

Diluted shares outstanding

143,086

146,115

144,359

146,410



(1)

See reconciliation of non-GAAP financial measures in table at end of press release.

 

 

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets (Unaudited - In thousands)



June 30,

June 30,


2014

2013

Assets



Current assets:



Cash and cash equivalents

$905,730

$876,048

Accounts receivable, net

359,593

318,349

Inventories

165,418

145,847

Prepayments, deferred income taxes and other current assets

125,468

108,605

Total current assets

1,556,209

1,448,849

Property, plant and equipment, net

434,277

411,433

Goodwill

289,312

274,829

Other intangibles

45,198

49,639

Deferred income taxes and other non-current assets

35,966

25,971

Total non-current assets

804,753

761,872

Total assets

$2,360,962

$2,210,721

Liabilities and Stockholders' Equity



Current liabilities:



Accounts payable

$85,405

$60,688

Accrued expenses

130,656

137,674

Deferred revenue

42,370

44,953

Income taxes payable

10,392

30,090

Deferred income taxes

717

627

Current portion of long-term debt

18

300,017

Total current liabilities

269,558

574,049

Non-current liabilities:



Deferred income taxes

10,716

9,895

Deferred revenue

16,352

11,928

Income taxes payable

5,318

3,564

Non-current portion of long-term debt

300,770

769

Total non-current liabilities

333,156

26,156

Total liabilities

602,714

600,205

Stockholders' Equity:



Common stock

566

568

Additional paid-in capital

1,117,639

1,025,064

Retained earnings

1,780,396

1,576,641

Treasury stock

(1,291,910)

(1,083,845)

Accumulated other comprehensive income

151,557

92,088

Total stockholders' equity

$1,758,248

$1,610,516




Total liabilities and stockholders' equity

$2,360,962

$2,210,721




 

Reconciliation of Non-GAAP Financial Measures (Unaudited)
(In US$ thousands, except share and per share data)

The measure, "non-GAAP operating income" is reconciled with GAAP income from operations below:


Three Months Ended

June 30,

Year Ended

June 30,


2014

2013

2014

2013

GAAP income from operations

98,486

86,165

405,087

354,824

Restructuring expenses (A)

6,326

-

6,326

-

Education, research and settlement expenses (B)

-

24,765

-

24,765

Non-GAAP operating income (excluding the impact of the restructuring, education, research and settlement expenses)

104,812

110,930

411,413

379,589

The measure, "non-GAAP net income" and "non-GAAP diluted earnings per share" are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:


Three Months Ended

June 30,

Year Ended

June 30,


2014

2013

2014

2013

GAAP net income

87,738

73,013

345,273

307,133

Restructuring expenses, net of tax (A)

4,222


4,222


Education, research and settlement expenses, net of tax  (B)

-

17,707

-

17,707

Non-GAAP net income (excluding the impact of the restructuring, education, research and settlement expenses)

91,960

90,720

349,495

324,840

Diluted shares outstanding

143,086

146,115

144,359

146,410

GAAP diluted earnings per share

$0.61

$0.50

$2.39

$2.10

Non-GAAP diluted earnings per share (excluding the impact of the restructuring, education, research and settlement expenses)

$0.64

$0.62

$2.42

$2.22

 

(A) 

The restructuring expenses relate to discrete employee termination benefits associated with the reorganization of our commercial and research and development teams. Management excludes restructuring activities from its evaluation of ongoing operations and believe investors benefit from excluding these charges to facilitate a more meaningful evaluation of current operating performance.



(B) 

The education, research and settlement charge relates to an agreement reached with the University of Sydney, in the fourth quarter of fiscal year 2013, to pay A$25 million (US$24.8 million) for the establishment of two perpetual academic chairs, the funding of future research in the fields of sleep medicine and biomedical engineering and the settlement of legal proceedings between the parties.




ResMed believes that presenting diluted earnings per share, excluding the impact of the charge for the restructuring, education, research and settlement expenses is an additional measure of performance that investors can use to compare operating results between reporting periods.




Management uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods.  Management believes this information provides investors better insight in evaluating the Company's performance from core operations and provides consistency in financial reporting.  Our use of non-GAAP measures is intended to supplement, and not to replace, our presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.





ResMed Inc. logo

Logo - http://photos.prnewswire.com/prnh/20140310/LA79234LOGO-a

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

News Channel 25 KXXV-TV
P.O. Box 2522
Waco, TX 76702

Phone Numbers:
Main: 254-754-2525
Tip Line: 254-757-2525

Links
Contact Us
KXXV Employment Opportunites
FCC Filings
Advertise on KXXV

Can't find something?
Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KXXV. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.